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SUMMARY
The design and execution of prevention trials for OA have methodological issues that are distinct
from trials designed to impact prevalent disease. Disease definitions and their precise and sensitive
measurement, identification of high-risk populations, the nature of the intervention
(pharmaceutical, nutraceutical, behavioral) and its potential pleiotropic impacts on other organ
systems are critical to consider. Because prevention trials may be prolonged, close attention to
concomitant life changes and co-morbidities, adherence and participant retention in the trial is of
primary importance, as is recognition of the potential for “preventive misconception” and
“behavioral disinhibition” to affect the ability of the trial to show an effect of the intervention
under study. None of these potential pitfalls precludes a successful and scientifically rigorous
process and outcome. As technology improves the means to measure and predict the OA process
and its clinical consequences, it will be increasingly possible to screen individuals for high-risk
phenotypes, combining clinical factors with information from imaging, genetic, metabolic and
other biomarkers and to impact this high-risk condition to avoid or delay OA both structurally and
symptomatically.
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Osteoarthritis (OA) is the most common specific arthritis condition, affecting 27 million
people in the United States in 20051. Knee and hip OA are generally considered to have the
greatest impact due to effects on ambulation2. OA of these joints accounted for 97% of the
total knee replacements and 8% of the total hip replacements for arthritis in 20043. OA,
however, is frequently a generalized condition, involving multiple joint sites, including the
hand, knee, hip, great toe, and spine, all of which can be associated with significant
symptoms and disability4–6.
In 2007, the Osteoarthritis Research Society International (OARSI) was awarded a contract
from the Federal Drug Administration (FDA) to review issues related to the design and
conduct of clinical trials for OA, particularly pertaining to agents purporting to effect
disease modification (See Introduction to Issue). Several categories of inquiries, and
Working Groups to examine them, were established, including Imaging, Biomarkers,
Definition of Disease State, Safety, and Prevention and Risk Reduction. This paper will
Jordan et al. Page 2













discuss the outcome of deliberations by the Working Group for Prevention and Risk
Reduction. This Working Group was composed of individuals from academia and the
pharmaceutical industry. The remit of this group was to examine potential outcome
measures, the desirable duration of, and population for, an OA prevention trial, and the
safety database and acceptable risk that would be required for prevention. Lastly, a research
agenda to inform these issues was requested. Through a series of face-to-face meetings,
telephone conferences, and electronic mail exchanges over almost 2 years, the members of
the Working Group discussed these relevant questions, reviewed literature as required to
inform answers, and presented the final product to a public forum attended by
representatives from the FDA, the OARSI, and the National Institutes of Health (NIH), and
academic and industry/private foundation communities.
Generally, clinical trials in OA have addressed three major types of outcomes: (1) symptoms
of pain, function, and stiffness; (2) structural disease progression; and (3) replacement of
affected joints. The clinical trials in OA to relieve symptoms of pain or stiffness and to
improve function may involve pharmaceutical or nutraceutical agents7, devices (i.e., braces,
shoe orthotics), or behavioral interventions, such as weight-reduction, exercise, or increased
physical activity8–12. The less common disease-modifying trials aim to demonstrate slowing
of the rate of structural progression, (frequently measured by change in joint space
narrowing on radiographs of the knee or hip13–15) and have employed pharmaceuticals or
neutraceutical with, for example, putative anti-oxidant properties, the ability to inhibit
cartilage degradative enzymes, impact bone turnover, modulate inflammation, or enhance or
induce cartilage repair and/or lubrication16,17. The goal of these trials is to prevent structural
progression of established disease, or to prevent disability or the need for total joint
replacement, an indicator of total joint failure, in those with established disease, ie tertiary
prevention. A third major type of OA trial involves evaluation of actions intended to assure
the safety, efficiency, and efficacy of joint replacement.
This report will address the primary and secondary prevention and risk reduction of
structural and symptomatic indicators of OA. These types of trials face specific hurdles
because the onset of OA can be insidious and progression slow, with consequently, the need
for trials of long duration, or the use of proxy measures with imperfect sensitivity and
specificity for development of OA clinical outcomes, to allow the trial to be feasible. This
report will discuss definitions, eligible populations and high-risk groups to whom initial
prevention efforts might be directed for proof of concept, and possible outcome/surrogate
outcome measures for primary and secondary prevention and risk reduction (Fig. 1). Then,
an example of a prevention and a risk reduction trial for knee OA, directed at the high-risk
group of those who are overweight or obese, and young athletes at risk of knee injury,
respectively, will be proposed. These example trial designs are directed at knee OA with the
understanding that OA in other joint sites (i.e., hands and hip) may have different
prevalences, different risk factor profiles, different natural history of development and
unique measures to define the disease state. Therefore, the approaches in these examples
may not be generalizable to OA affecting joints other than the knee. In these examples, the
recommended duration of a trial and appropriate database for safety will be outlined.
Finally, ethical issues surrounding the conduct of clinical trials for OA prevention will be
introduced.
Definitions of prevention and risk reduction
For the purposes of this report, prevention refers to those agents or actions that curtail or
delay the onset or new occurrence of clinically diagnosed OA at the joint site of interest, in
someone initially without evidence satisfying the clinical definition of the condition.
Components of this definition may include structural evidence, e.g., on radiographs, and
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characteristic signs and symptoms, e.g., bony enlargement, crepitus, and/or pain. This report
will not address tertiary prevention, or treatment, to modify the progression of established
disease or achieve the maximum accommodation of living with established disease. Risk
reduction refers to decreasing specific and modifiable risk factors associated with the
development of OA, in an attempt to decrease the likelihood of developing OA or to delay
its onset. For example, since obesity and overweight are strong risk factors for knee OA, a
weight loss intervention could be evaluated to determine its ability to reduce the risk of
developing knee OA in the obese. Similarly, since joint trauma, with its frequently resultant
altered biomechanics, is a strong risk factor for the development of OA, an intervention to
alter abnormal biomechanics in those with joint injury could also be considered in a
preventive context for OA. Further, an intervention to prevent joint injury in the first place
would be an example of risk reduction. It must also be acknowledged that an intervention
may be both a preventive measure and a risk reduction measure, i.e., a weight loss
intervention would fit both categories though the outcomes would differ (incident OA vs
loss of weight).
Because the presentation of OA is frequently generalized, i.e., occurs in more than one joint
in more than one joint group, an intervention could be applied in someone with OA in one
joint site, in order to prevent the development of OA in another joint site unaffected at the
start of the trial. For example, those with hand OA could be the subject of a prevention trial
to prevent the development of OA in the knees or hips6. This situation blurs the distinction
between incidence of new disease and progression of established disease, and may need to
be considered on a case-by-case basis, with statistical methodology applied to allow for the
non-independence of multiple joints within the same person. This also suggests that
collection of information about joints beyond the target joint should be considered at the
beginning and throughout the trial, both for the purpose of recognizing important secondary
effects of the intervention and for identifying potential safety signals of the intervention.
Study populations
In a prevention trial, the optimal study population to demonstrate efficacy most efficiently
would be at high risk for future OA, but free of full evidence satisfying an accepted and
operational disease definition. However, the initial testing of an intervention on a high-risk
population is not without drawbacks, as this may limit generalizability, necessitating further
testing on others with varying degrees of risk. Or, the efficacy of agents which might be
effective in those of lower risk, but prove ineffective in the “high-risk” population, would
remain undiscovered. Ultimately, the study population selection cannot be dictated and is
dependent upon the definition of disease that is employed and overall goals of the trial.
A prevention trial study population can be selected to represent the three major domains of
disease definition related to OA: (1) structural compromise, (2) pain and other symptoms,
and (3) impaired function. Additionally, physiological/immunological/genetic locally or
systemically measured biomarkers, such as synovial fluid aggrecan, serum C-reactive
protein (CRP) or cartilage oligomeric matrix protein (COMP), urinary type II collagen
telopeptides (uCTX-II), or combinations of biomarkers, might be incorporated to either
define an at-risk population or to exclude individuals from selection into a prevention trial18.
Further, population selection can be predicated on addressing each of these domains
singularly or in combination19. For discussion of the current state of qualification of
biomarkers for OA, the reader is referred to the article in this issue on Biomarkers.
Eligible study populations for trials to prevent structurally-defined OA
If the eligible population for a prevention trial is to be free of structurally-defined OA, one
option for defining a “disease-free” population includes enrollment of persons with
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Kellgren–Lawrence (K–L) radiographic grades 0 or 1. Decision-making based on the
selection of a population with a K–L score of K–L = 0 vs K–L = 1, which is designated as
“doubtful OA” must acknowledge that there is an embedded probability that individuals
with a K–L = 1 have early OA20, or the underlying conditions leading to OA, but have not
yet been identified definitively radiographically. This probability should be factored into
estimating the sample size and developing data analytic strategies. Similar concepts apply if
the study population lacks knee OA, defined as the absence of a definite osteophyte.
Currently, there are very limited data organized to inform these design issues; this is the
rationale for this report including a call to identify and organize data to support making
evidence-based design choices.
An example of the type of data needed comes from the 15-year study of the natural history
of knee OA development (the Michigan Bone Health and Metabolism Study) encompassing
660 women who were aged 24–44 at the 1992 study inception. The women were recruited
from a population-based sample to increase the likelihood of generalizability of the findings.
Radiographs, taken every 3 years, were scored by two radiologists using K–L definitions for
OA knee severity.
The probability of moving from one K–L score to the same or a different K–L score in a 3-
year period was estimated using Markov transition modeling. Estimating the probabilities of
transitioning from a K–L score of 1 (proposed here as an example for a prevention trial) to
other K–L scores reveals the impact of age and body mass index (BMI) and provides
evidence to define inclusion and exclusion criteria in the prevention trial.
At age 50, the probability that a K–L = 1 score would remain at a K–L = 1 score 3 years
later was 54–59% when BMIs ranged from 25 kg/m2 to 35 kg/m2 [Fig. 2(A)]. The
probability of transitioning from K–L = 1 score to K–L = 2 score in a 3-year period ranged
from 8% in non-obese women to 15% in women with a BMI ≥ 35 kg/m2 [Fig. 2(B)]. The
probability of transitioning from a K–L = 1 score to a K–L = 3 score in a 3-year period is
less than 2% (data not shown graphically). This evidence-based approach increases the
likelihood of having efficiently designed trials of prevention practices to forestall the
development of knee OA.
Efforts are underway to define structural changes of knee OA by techniques other than the
standing knee radiograph. For instance, static magnetic resonance imaging (MRI) to define
OA based on morphologic changes in cartilage, bone or other soft tissues21 or functional
magnetic resonance imaging (fMRI) or other types of MRI measures (such as delayed
gadolinium-enhanced MRI of cartilage [dGEMRIC], T2-mapping, T1rho, sodium imaging,
etc) to define OA based on compositional changes in cartilage, bone or other soft tissues22,23
may become modalities of choice. Currently, there is no agreed upon definition of OA based
on these technologies. However, the field is rapidly evolving, i.e., the OARSI FDA Initiative
Imaging Working Group is currently developing criteria for the early diagnosis of knee OA
using MRI, and these developments must be anticipated in developing future trials (See
article on Imaging in this issue).
Eligible study populations for trials to prevent symptoms of OA
If the eligible population lacks characteristic defining symptoms, especially pain or stiffness,
the limits of allowable symptoms must be carefully defined, including how pain is to be
assessed, its severity and duration, and the allowable frequency for transient pain, and
potentially whether or not pain in joints apart from the target joints are considered
informative. The use of usual and rescue medications, such as analgesics or non-steroidal
anti-inflammatory drugs (NSAIDs), also needs to be factored into the methodologic strategy
to assess symptoms of OA24. Depending upon the mode of action of the agent under study,
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it may be necessary to disallow some usual or rescue medications to decipher the effect of
the intervention unambiguously. For example, if the mechanism of action of the agent to be
used effects pain relief through disruption of bone turnover, it might be necessary to exclude
the use of drugs that affect bone turnover, such as bisphosphonates. If a drug is related to
narcotics, it might be necessary to exclude the use of narcotics as rescue medication. Again,
these issues, critical to the design of prevention trials, cannot be dictated and must be
decided in the context of the trial under consideration.
Eligible study populations for trials to prevent functional decline from OA
If the eligible study population is to be free of functional performance impediments,
investigators will need to determine whether inclusion criteria are based on self-report
instruments or performance-based assessments. There are numerous questionnaire-based
instruments to characterize functional status (See article on Functional status measures in
this issue). For the selection of a study population, it is particularly important to choose an
instrument or combination of instruments that have a known specificity (the known
probability of truly being free of functional compromise), and that specificity should be
relevant to the population from which the prevention trial population will be recruited. The
use of performance-based assessment in prevention trial recruitment is limited by the
relative absence of normative data in persons younger than age 65, thereby precluding the
ability to estimate the probability of any specific assessment value’s actually representing
the disease-free state for a prevention trial. Further, there are many determinants of function
which may or may not be directly relevant to OA. Alternatively, these measures may be
considered to be estimates of an “at-risk” state and therefore eligible for study in a
prevention trial; it is important that the predictive capacity of these performance measures
over a period of time for increased compromise be known.
Use of biomarkers to define eligible study populations for prevention trials in OA
If the eligible study population will be selected based on physiological or immunological
biomarker measures, there are at least two expectations. First, there must be adequate
information to discern when a specific value of the biomarker(s) truly represents a “disease-
free” state and, second, information about the rapidity of the biomarker change (if treated as
a continuous variable) or conversion (if treated as a discrete variable) in relation to the
development of disease, must be known and available. Additionally, the biomarker must
have been previously validated against a clinically relevant endpoint for its use as a
surrogate measure25. Even if the biomarker is used only as a criterion for inclusion or
exclusion for participation in a prevention trial, it must have sufficient evidence of
predictive relevance to warrant its application. Further discussion of this topic is found in the
article on Biomarkers.
High-risk groups to target for prevention and risk reduction
For primary prevention and risk reduction, careful characterization of the relevant risk factor
of interest is as critical as being able to define the absence of OA. It is important to be able
to (1) define and measure the risk factor unambiguously, and (2) know the relative
contribution of the risk factor to OA disease development, the average duration to disease
manifestation among those with and without the risk factor, and the prevalence of the risk
factor in the population. Clinical risk factors for OA may be joint-site specific, i.e., rupture
of the anterior cruciate ligament (ACL) as a risk factor for the development of knee OA.
Other risk factors may exert systemic effects on risk of OA in multiple joints. The latter
situation includes factors such as age, female gender, overweight and obesity, endocrine
disorders, and family history or genetically-defined population subgroups. Although not all
of these are modifiable, they may influence participant selection criteria in certain trials.
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As our measurement tools become increasingly sensitive and precise, it may be possible to
classify the risk status of individuals and groups based on characteristics such as cartilage
lesions on MRI, levels of biomarkers associated with OA development, or possession of a
specific genotype.
Sample trial design for prevention of knee OA in overweight and obese
■ The following is presented for illustrative purposes only, and should NOT be
considered a prescriptive mandate for the design of a prevention trial. Further, as
definitions of at risk populations change and measurements of the disease process and
outcomes advance, it is expected that design features of such a trial would necessarily
evolve as well. It is critical to enrich the probability of including individuals who may
develop knee OA in a shorter and feasible time frame that acknowledges that clinical
trials of long duration are not only costly, but are difficult to implement (i.e., to conduct
an intervention without drift or maintain a study group compliant with the protocol,
etc.). Including persons with an increased likelihood of developing disease will improve
the ability to determine the intervention’s effectiveness in preventing disease, but may
limit generalizability.
Proposed study population
The study population for a primary or secondary prevention trial should be structured to the
proposed intervention. A reasonable “high-risk” study population for a prevention trial could
consist of ambulatory, community-dwelling men and women aged 50–65 years with: (1) no
more than a “questionable” osteophyte (K–L = 1) in the medial or lateral tibiofemoral
compartment (2) knee varus or valgus malalignment (angle ≥ 2° and ≤ 10°); (3) BMI ≥ 30
kg/m2 and ≤ 45 kg/m2; (4) sedentary lifestyle, i.e., no participation within the past 6 months
in an exercise program that incorporated more than 30 min/week of formal exercise; and, (5)
the absence of interview-determined knee pain or limited function for a month-long time
period. Scores on either questionnaire-based or performance-based functional assessment
will reflect values considered in the “normal” range for men and women in the 50–65 year
age range. A detailed record of medication use should be collected at baseline and for each
specific follow-up testing interval.
Rationale for criteria
■ Use of K–L = 1 rather than K–L = 0, 1 should increase the likelihood that individuals
will develop OA20.
■ A 30 < BMI < 45 kg/m2 is likely to include a population that is obese but able to
participate in a designated intervention, and for which normative measures are
interpretable. The range of BMI should be evaluated for population groups of shorter
stature, such as first generation Asian enrollees to BMI of 25–35 kg/m2.
■ Potential study participants with a BMI > 45 kg/m2 should be considered for
exclusion because of the difficulty in using computerized tomography and MRI
equipment to characterize hard and soft tissue structures. Additionally, in this group,
there is a lower exercise compliance rate associated with high BMIs26.
■ Including only those with moderate malalignment (varus or valgus knee angle ≥ 2 and
≤ 10°) will potentially allow more rapid development of disease, because medial and
lateral knee OA progression is strongly associated with moderate malalignment, and
this may or may not be independent of body size27. However, this is not absolute, since
data supporting the role of malalignment in the development of new knee OA is
controversial28,29.
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Interventions could be pharmacologic or non-pharmacologic. Importantly, an intervention in
a primary or secondary prevention trial has unique elements in that (1) implementation is
likely, but not definitely, to require a protracted administration period; (2) the administration
cannot generate risk of accentuating other potential on-going disease processes; and (3) a
careful weighing of the costs and benefits must occur. For example, bariatric surgery might
be considered a candidate intervention for a primary prevention trial for OA, but its use
imposes unique consideration for other heath costs and risks of morbidity and mortality. One
way to address this issue could be to append an ancillary study for prevention of knee OA to
an on-going trial of bariatric surgery for other outcomes. An active drug (unknown at this
point) could be directed toward decreasing inflammation and/or pain or improving weight
management. A functional intervention might include measures to modify alignment and/or
build strength. A behavioral intervention could be directed toward increasing physical
activity, changing the type of physical activity, or modifying dietary practices.
It is also possible that a preventive intervention might not have to be administered over
prolonged periods of time. Such a situation might obtain in the setting of acute joint injury,
in which hypothetical Agent X might be injected into the injured joint weekly for 4 weeks.
Assessment of such a regimen could improve the feasibility and tolerability of delivering the
intervention itself, but would not eliminate the need for prolonged assessments to ascertain
whether the agent inhibited the onset of OA and whether it is safe.
Primary outcomes
If the trial hypothesis is that an intervention in a prevention trial among obese adults with no
or doubtful evidence of radiographic knee OA (K–L = 0, 1) will be associated with a
delayed onset of knee OA compared to the placebo group, this delay could be reflected in
two co-primary outcomes: less symptom report and minimal structural change in relation to
the untreated group. Candidate measures to detect these areas include changes in: (1) K–L
score or minimal joint space and (2) questionnaire-based pain assessment. Other potentially
relevant outcome measures could include newer technologies once they have been validated,
such as MRI with or without T2-mapping to assess morphological changes in joint structures
or articular cartilage degradation and/or bone marrow lesions. As imaging and molecular
techniques advance to the stage where they could be surrogates of downstream clinical
outcomes, it may be that an intervention might be able to show a primary effect on structure
of the OA process, regardless of its immediate effect on symptoms. While examples of
prevention in other medical conditions abound, e.g., interventions directed toward lowering
serum cholesterol or altering lipid profiles to prevent future cardiovascular events30,31, or
altering bone mineral density to prevent osteoporotic fractures32, it is unlikely that
requirements for a proposed intervention to affect relevant clinical outcomes would be
waived entirely.
Secondary outcomes
Secondary outcomes could include some or all of the following largely predicated on the
nature of the proposed intervention: (1) clinical measures of function, pain and mobility; (2)
mechanistic measures of the OA disease pathways such as knee alignment, knee external
adductor moment, knee joint compressive and shear forces, and; (3) biomarker measures of
pro-inflammatory molecules (e.g., interleukin-6 (IL-6), Tumor Necrosis Factor-α, CRP) and
joint metabolism (e.g., uCTX-II, COMP); (4) lower extremity strength and power; (5) limb
proprioception; and (6) abdominal and thigh fat depots measured by CT; (7) adverse effects
associated with the intervention; and (8) quality of life.
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In addition to OA outcome measures, investigators need to select or develop appropriate
measures of intervention-related processes and adherence to the intervention.
Study time line
Depending upon the factors discussed above, a primary prevention trial is likely to require a
10-year follow-up with data collected from participants at 1 or 2-year intervals. The interval
distance should be based on time required to detect meaningful differences in the measures
of interest and motivate subjects to maintain optimal participation in the trial. For example,
MRI, knee X-ray, gait, and strength might be measured biannually (years 2, 4, 6, 8, and 10),
while biomarker levels might be assessed every 3–6 months. Proposed trials of shorter
duration, with proper justification of clinically relevant outcomes and safety monitoring,
would likely improve feasibility.
Sample trial design for prevention of knee OA by preventing knee injury
Many of the issues above also apply to trials of injury prevention, but the latter have a
number of unique, key design features worthy of separate discussion and illustrated by a trial
of an educational/exercise intervention vs an attention control to prevent knee injury in high
school female basketball players. This is an example of a risk reduction trial to prevent
injury that might later lead to knee OA.
Selecting a sample/population
Injury prevention trials must identify populations at considerable risk of the relevant injury.
Low risk populations are inefficient to study because event rates are minimal, requiring very
large samples or longer trial duration, which may lead to contamination across study arms
and considerable attrition of study participants. Sports teams, military trainees and other
such groups exposed to high levels of demanding physical activity are appropriate at-risk
populations.
Unit of randomization
Such prevention studies often require cluster-randomized designs, in which the unit of
randomization is the group, not the individual subject. These may include sports teams,
schools, sports leagues, or even towns. For the trial of female basketball players, the cluster
group is the high school team. The rationale for randomizing at the group level is to reduce
contamination, or diffusion of the intervention to the control group. For example, if two
basketball players on the same team are randomized to separate arms, the player randomized
to receive exercises may show the exercises to the player in the control group. Cluster
randomization reduces this risk. Furthermore, cluster randomization permits the group to be
incorporated into the intervention. When an entire school is randomized to an educational
intervention arm, the investigators can display injury prevention educational posters in the
school and not worry about contamination. Cluster-randomized designs are typically costly
in terms of sample size because each observation is not independent. The more similar the
outcomes are among members of the group, and the larger the cluster group, the greater the
sample size needed to overcome the non-independence.
Intervention protocol
Interventions in injury prevention trials must be delivered in a standardized fashion at all
intervention sites. This requires training, reliability assessment, site visits, and logistical
work to ensure that the intervention is administered similarly across diverse settings. In this
example, a basketball injury prevention program allocated at the school level needs to be
delivered identically despite differences in the gyms, practice schedules and coaches’ styles
in different schools.
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Assessments must be done in a standardized fashion at regular intervals using well-defined,
reproducible outcome definitions. In many trials the outcome is injury, but investigators
must clarify what constitutes an injury (a sore knee for an hour? a day? with swelling,
defined by whom? had to leave practice or game? had to miss next game? radiographic or
imaging findings, e.g., ligamentous injury, meniscal injury, fracture?). This assessment
should ideally be made by an observer blinded to random intervention assignment.
Statistical analysis
The analysis of cluster-randomized intervention trials must use techniques (such as
generalized estimating equations) that account for clustered observations33 or risk artificially
lowering variance estimates and over-stating the statistical significance.
Methodological considerations for prevention trials
Study design
As these examples illustrate, the double blinded, randomized, placebo or active comparator
study design is the gold standard, but its appropriateness is dependent upon the agent and the
availability of known effective interventions for primary preventions. Many likely
interventions may be difficult or impossible to blind completely. Further, many potential
primary prevention interventions, such as the injury prevention trial, may be more
effectively delivered using cluster randomization, where the community is the unit of
analysis, rather than the individual33. In this case, contamination related to community
behavioral or other change can influence results and must be rigorously addressed34.
Therefore, selection of study design for the trial will be dependent upon intervention, the
degree to which individual implementation is feasible, and the capacity to include an
effective placebo.
Adherence
It is a particular problem for long-term interventions, particularly if participants do not
readily perceive benefit from continued participation or experience other barriers. Both the
active intervention and placebo groups will require supplemental behavioral components to
maintain adherence, and the inclusion of an adherence specialist on the study team may be
wise.
There are also organic factors that may influence adherence. It may be appropriate to assess
for depression symptoms and design interventions and intervention monitoring to address
their impact in terms of both individual behaviors as well as interactions of depression
therapy with the intervention for OA. Female enrollees are likely to be in the midst of the
menopause transition and the degree of symptoms and stage of the transition are likely to
influence both behaviors and potentially structural tissue responses. This suggests that
adherence management needs to be prepared to deal with concomitant symptomatic
conditions and potential interventions associated with those symptoms. The proposed age
range is likely to reflect other competing illness processes that may affect adherence, as well
as directly impact intervention effectiveness and potential for side-effects.
Recruitment
It is the life-blood of any clinical trial; however, recruiting for a primary prevention trial
imposes requirements that are not always evident in treatment trials. Recruitment could be
enhanced by using complementary strategies coupled with a system that provides feedback
on each strategy’s effectiveness and cost35. Mass mailings and media (newspaper,
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television, internet) may be effective in some settings. Depending upon the age of the
primary prevention target population, having strong ties with local aging service networks
and access to senior centers, churches, drug stores, shopping malls, and other sites where
older adults gather could be important but may be ineffective for the population 50–65
years. Most health science centers maintain a large database of adults who have signed
consent to be contacted about participating in future clinical trials; however, it is important
to identify why these adults are associated with such registries and if their registration is
associated with diseases that may impinge on the intervention or decrease the likelihood that
they are going to be free of OA.
Experience has proven that on-going monitoring of the recruitment process is necessary to
achieve study goals and to review recruitment activities, plan new activities, and monitor the
number of contacts24. Close attention should be given to the gender and minority
frequencies of those who qualify for, and enroll in, the study.
Safety database for trials of prevention of OA
Because a prevention trial for OA could involve an intervention with active agents
administered to otherwise healthy individuals, or to individuals with co-morbid conditions,
for extended periods of time, the safety database must be extensive and involve information
from multiple organ systems. The extent of this safety database may depend upon the
intervention. For example, systemically-administered interventions may have pleiotropic
effects, e.g., statins or bisphosphonates36–39, reinforcing the need to monitor multiple organ
systems for toxicity. A more localized intervention, such as an unloading brace, might not
require the same degree of vigilance for safety in remote organ systems. Observations must
also be long in duration, particularly for agents that might impact the immune system and be
associated with infections or subsequent development of cancer. Finally, when trials are of
considerable duration, such as in these cases of OA prevention, careful monitoring of
evolving technology that might impact the long-term assessment of outcome must also
occur. See article on Safety as part of this issue.
Ethical issues for prevention trials
As recently reviewed40, rheumatology clinical trials may involve some issues that pose
specific ethical concerns. This may particularly be the case in prevention trials for OA. First,
since currently no clearly effective agents exist, novel agents to be used in primary
prevention must first include substantial testing on healthy volunteers or people with early
disease to establish viability. Prevention trials necessarily involve people who may not have
the disease in question, who may not ever get the disease, or who might experience a
relatively benign course even with no intervention. Further, for a condition such as OA,
which develops over years, any effective agent for prevention would likely need to be
administered for a prolonged time, possibly beginning at an early age. The potential for
multi-system toxicity must be monitored, especially in younger individuals who may be of
reproductive age when the agent is started.
Some preventive interventions may be directed at the population level, rather than provide
benefit to a specific individual. An example of this would be a vaccine study. In this
instance, studying a treatment in a person with disease can be profoundly different than
studying an intervention in healthy people. Studies in other diseases have shown that study
participants may have misconceptions about the potential effectiveness of a preventive
intervention and/or may have inflated estimates of the likelihood that they will be
randomized to get the active agent, and may have exaggerated impressions of the likelihood
that the intervention will be personally effective for them. Simon and colleagues have called
this the “preventive misconception,” defined as “the overestimate in probability or level of
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personal protection that is afforded by being enrolled in a trial of a preventive
intervention”41. This can be particularly problematic when accompanied by “behavioral
disinhibition” or the adoption of behaviors that may pose a risk to the participant or others.
This has been observed in persons participating in a HIV vaccine trial, in which individuals
had an increase in risky behaviors41. In the case of OA, various scenarios could be
imagined, in which behavioral disinhibition could occur. One could imagine that someone
with a strong family history of OA, or even someone who possessed a very high-risk
genotype, might be less vigilant about maintaining a normal weight because of a false
expectation that the preventive agent he/she received in a trial will be effective and protect
him/her from his/her increased risk of OA. These issues emphasize the critical importance of
the informed consent process in OA trials, particularly those for prevention.
Recommendations for future research
First and foremost is the requirement that research continue to work to refine definitions of
OA, utilizing genetic, biochemical, and imaging biomarkers and psychometrically valid
questionnaires and performance measures, with the goal of diminishing ambiguity in the
currently used metrics and increasing their clinical relevance. Collection of extensive
biological specimens, e.g., serum, plasma, DNA, RNA, urine, should be a part of all of these
on-going and future studies.
Observational studies with both short and long-term follow-up can be particularly helpful in
this regard, to define molecular, structural and symptomatic correlates of disease and to
identify risk factors predictive of the development of disease and its clinical impact.
Attention to gender and minority inclusion, with the requisite consideration of distinct issues
regarding their propensity to participate in prevention trials, should be a part of this research
agenda. Observational studies can be particularly helpful in the following activities:
• Evaluation of existing datasets with particularly long follow-up times (10, 20 or
more years) in order to identify risk factors that may be exposed long in advance of
disease onset.
• Extended follow-up as adults of cohorts established during childhood, adolescence,
and early adulthood, for the development of OA.
• Extended, detailed follow-up of inception cohorts of those with acute joint injury,
with detailed information regarding the events and treatment modalities applied in
the acute setting, as well as other potential risk factors.
• Evaluation of existing datasets with detailed genetic, biomarker, and imaging data
to expand our information about various OA phenotypes along the continuum from
molecular to pre-radiographic OA, to radiographic to symptomatic OA.
• Addition of short follow-up times (i.e., months), to studies of existing cohorts to
obtain sensitive, dynamic imaging and other biomarker data to aid prediction of the
development of structural and clinical disease.
• Evaluation of distinct ethnic/racial sub-populations to ascertain accurate assessment
of the burden of disease in these groups, differences in risk factor profiles, and
genetic, imaging, and biomarker sub-types in order to tailor trials to relevant
groups, (i.e., differences in BMI that might be used to screen Asians or African
Americans into prevention trials for the overweight/obese).
• Methodological studies of distinct threats to validity of prevention trials and their
execution, related to cultural differences in attitudes toward trial participation and
risk factor reduction; techniques to maximize adherence and retention; and ways to
measure and overcome biases such as preventive misconception and behavioral
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disinhibition. As one example, the use of technology, such as hand-held devices
and the Internet, for participant recruitment, retention and data collection, is
becoming more widespread and will continue to evolve. The study of the impact of
such methods upon prevention trials in general will likely inform future prevention
trials for OA.
An additional future direction may be a multi-center clinical trial of a non-pharmacologic
intervention, alone and in combination with a pharmacologic co-therapy, that can alter
mechanisms in the pathological pathway (e.g., decrease knee joint loading and reduce
inflammation) to OA and thus lower its incidence. The 2009 NIAMS Roundtable presented
a roadmap for how prevention trials should be organized. For large multi-center trials,
NIAMS will identify the most qualified investigators who will be required to first establish
the need for a larger trial with results from a planning grant or similar study. This will allow
applicants to demonstrate their abilities to design and manage clinical trials before launching
a full-scale project. The large-scale project should be comprehensive, incorporating clinical
(e.g., pain, function), mechanistic (e.g., inflammation and knee joint loading), and structural
(e.g., quantitative cartilage morphology with qMRI, semi-quantitative whole joint scoring)
outcomes. Demonstrating the ability to identify and target people who are at high-risk of OA
will be crucial as this will lay the foundation for primary prevention efforts.
Secondary prevention is equally important. Knee trauma, such as ACL or meniscus injury, is
a strong predictor of subsequent knee OA. Considering the young age at which many of
these injuries occur, knee joint replacement at a relatively young age is a distinct possibility,
possibly followed by a second replacement after 10–15 years. A secondary prevention trial
with outcomes related to the risk of knee replacement would have important public health
implications. Knee and hip strengthening in young adults with knee trauma to reduce the
risk of knee replacement would be an example of a secondary prevention trial. A synopsis of
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Structural abn’l = structural abnormality.
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Three-year transition probabilities of K–L score of 1 (doubtful OA) staying at a K–L = 1 or
progressing to a K–L = 2 to OA as a function of age (years) and BMI (kg/m2): designing a
prevention trial of knee OA. (A) Transition probability of K–L = 1 score staying at K–L = 1;
(B) Transition probability of K–L = 1 score to a K–L = 2 score, indicative of OA.
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